Navigation Links
Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009
Date:3/9/2009

SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced its fourth quarter and full year financial results for 2008 and will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. EDT (1:30 p.m. PDT) on March 10, 2009. Interested investors may participate in the conference call by dialing 877-719-9791 (US) or +1-719-325-4828 (international). Participants may also access both the live and archived webcast of the conference call, which will be available for at least 10 business days following the call, from the homepage and the investor relations section of Nile's website at www.nilethera.com.

Year-end Summary

During 2008, Nile made important progress in the clinical development of CD-NP for the treatment of patients with acute heart failure. Nile executed a focused clinical development plan for CD-NP, which included starting and completing a Phase 1b study to establish the maximum tolerated dose (MTD) and to assess the pharmacologic effects of CD-NP on blood pressure and renal function in stable heart failure patients, and also starting and completing a Phase 2a study to assess hemodynamic and renal effects of CD-NP in acute heart failure patients. Nile believes that the results of these studies indicate:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min in stable and acute heart failure patients;
  • CD-NP blood pressure effects were dose-dependent and well characterized in chronic heart failure patients;
  • In the anticipated therapeutic dose range, CD-NP produced a statistically
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics Shareholders Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
2. Cell Therapeutics Announces Receipt of NASDAQ Listing Update
3. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
4. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
5. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
6. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...., Dec. 1 To address the emergence...its potential, a group of individuals and companie... Industry Association (SynBIA) in Cambridge, Massa... to provide a forum for individuals and commercial...s opportunities and its challenges, and advocate f...
(Date:12/1/2009)... 1 Expanding its European reach fo...arasota has appointed Lake Chemicals and Minerals ...d near Birmingham, England. ,, Osprey breeds t...ricultural, waste water, and environmental markets...rain fields, and clean up industrial and marine sp...
(Date:12/1/2009)...se level storage is now available to small and med...he bank. , (PRWEB) Decemb... ), a medical imaging software company, announced...ge service. The PacsDrive service enables small an...rchive medical imaging in compliance with HIPAA re...
(Date:12/1/2009)... Palatin Technologies, I...S. Patent and Trademark Office has issued U.S. Pat...ide Constructs." The claims in the issued patent ...triuretic peptide receptor A (NPRA), including PL-... ,, "Our natriuretic compounds, including PL-39...
Breaking Biology Technology:Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
... DIEGO, CA, Dec. 6 /PRNewswire-FirstCall/ - Nventa...nnounced that the Company,has completed enrollment...ents in its Phase 1 dose escalation trial examinin...ents with cervical dysplasia, a precursor to,cervi...c vaccine targeting,human papillomavirus (HPV)-rel...
...MINGHAM, Mass., Dec. 6 Transport Pharmaceuticals,... for the topical,treatment of dermatological condi...e 2007 Frost & Sullivan North American Technology ...rokinesis-enabled drug delivery. Frost,& Sullivan,...sport at its,annual North American Excellence in H...
... YORK, Dec. 5 Driven by an aging population and,c...surgical and trauma,wound treatment market is expe... and grow to $7 billion by 2011, according to Woun...nds, a new report by Kalorama,Information., With ... United States,alone and millions performed annual...
Other Biology Technology:Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 2Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 3Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 4Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 5Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award 2Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award 3Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award 4Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011 2
(Date:11/30/2009)...rgh team overcame a major hurdle plaguing the deve...lead to more efficient catalysts used to produce h...earchers reported Nov. 29 in Nature Materials th...y in metallic nanoparticles, the vaunted next-gene...treme heat. , Gtz Veser, an associate professor ...
(Date:11/30/2009)... LSU Health Sciences Center New Orleans School of ...titute of Child Health and Human Development (NICH...omen,s Hospital, and Harvard Medical School, have ... servings of sugar- sweetened cola a week prior to...sk of developing diabetes during pregnancy. Liwei ...
(Date:11/30/2009)...perimental Biology are pleased to announce that D...he Scientifique (CNRS) in the Universit de Nice-So...Outstanding Paper Prize. ,The prize is awarded in ...ntended to encourage young scientists, says Hans ...t ,we truly appreciate when authors submit their v...
Breaking Biology News(10 mins):First metallic nanoparticles resistant to extreme heat 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Visage Imaging Signs University of Chicago 61546 1Visage Imaging Signs University of Chicago 61546 2Visage Imaging Signs University of Chicago 61546 3HealthSouth Prices Offering of Its 8 125 25 Senior Notes Due 2020 61543 1HealthSouth Prices Offering of Its 8 125 25 Senior Notes Due 2020 61543 2HealthSouth Prices Offering of Its 8 125 25 Senior Notes Due 2020 61543 3HealthSouth Prices Offering of Its 8 125 25 Senior Notes Due 2020 61543 4Liquid Tissue 28R 29 Patent Licensed for Amyloidosis Proteomic Assay 6349 1Liquid Tissue 28R 29 Patent Licensed for Amyloidosis Proteomic Assay 6349 2
...ming just a few calories from the daily diet can d... it may help lessen the effects of aging. , Scient... Aging have found that eating a little less food a...duce or even reverse aging-related cell and organ ...onth in the journal Antioxidants and Redox Signali...
...A AIDS Institute and the Institute for Stem Cell B...t time that human embryonic stem cells can be gene...ure T-cells, raising hopes for a gene therapy to c...of July 3 in the online edition of the Proceedings...t is possible to convert human embryonic stem cell...
...me disease incidence has skyrocketed from 497 case...tics were collected) to a record 23,763 in 2002. ...ted by a vector that picks up the pathogen during ...n and central United States, the spirochete bacter..., Ixodes scapularis, which feed on a wide variety ...
Other Biology News:Cutting calories slightly can reduce aging damage 2Cutting calories slightly can reduce aging damage 3UCLA researchers develop T-cells from human embryonic stem cells 2A new view on Lyme disease: Rodents hold the key to annual risk 2A new view on Lyme disease: Rodents hold the key to annual risk 3
...lance increases your lab productivity and allows y...tory compliance. Move ahead beyond traditional pap...cure networked data system. *Instruments supporte..., XS, XP, PR, SR, PG-S, PG, SG, AT, MT, UMT, AB-S,...
...rification Kits enable rapid analytical to medium ...s produced from appropriate vectors. Sufficient re... target protein under native or denaturing conditi...arose, which specifically retains STag fusion prot...
Baker's yeast (S. cerevisiae) Hexokinase and glucose-6-phosphate dehydrogenase from Sigma-Aldrich
...Polyclonal Antibody Epitope: aa 16-25 of human...ecommended Storage: Store vial at -20 C prior to ...extended storage aliquot contents and freeze at -2...g. Family: Other Sub-Family: not assigned-...
Biology Products: